Pharmaceutical Executive-08-01-2020

Click here for a link to open the Pharmaceutical Executive August 2020 issue in an interactive PDF format.

Our latest review of biopharma financial performance reveals solid growth rates in enterprise value and rebounding value-to-sales numbers—proving once again the business imperative of regaining and sustaining shareholder value.

What’s all the mystery about?

How one COVID-sparked model could help usher in needed reset.

How pharma leaders can convert data collected for compliance purposes from a cost center into a critical success factor.

How “Contractual Genericization” could revitalize pharma and reframe the public conversation.

In adjusting to the long-term aftershocks from the coronavirus pandemic, pharma companies will need to focus on change in three core areas.

Patrick Soon-Shiong, the billionaire biotech entrepreneur and owner of NantWorks, a network of health startups, discusses his companies’ COVID-19 vaccine candidate and its “fighting chance” to outsmart the virus’s hidden tricks through merging supercomputing and modernized DNA delivery.

Latest reform brouhaha requires a united response focused on real solutions.

While exposing gaps in the way pharma acquires and uses data, the pandemic has also fostered a new spirit of information sharing that bodes well for future collaborations.

Collaboratives, company initiatives address systemic barriers.

The need for clear transparency around use of real-world data, AI.

Their application for security and anti-counterfeiting purposes continues to evolve, especially in combination with digital technology.

Budget battle threatens efforts to bolster Europe’s pharma strategy.